Please login to the form below

Not currently logged in
Email:
Password:

Mereo BioPharma’s Richard Bungay to step down

Will leave CFO and COO roles in April 2017

Mereo BioPharma's Richard Bungay is set to step down from his roles as chief financial officer and chief operating officer in April 2017.

Bungay joined the UK-based clinical stage biopharmaceutical firm in July last year, taking on responsibility for Mereo BioPharma's finances, manufacturing and quality operations.

He has previously held the chief financial title at Glide Pharmaceutical Technologies, Chroma Therapeutics and Verona Pharma, remaining as a non-executive board director at both Glide and Chroma.

Prior to these roles, Bungay worked at Celltech Group as director of corporate communications and planning, and served as finance director for AstraZeneca's respiratory and inflammation therapy area.

Dr Peter Fellner, chairman of Mereo BioPharma, said: “On behalf of the board I would like to thank Richard for his significant contributions to the successful launch of the company and the subsequent introduction of its shares on AIM.

“We wish him every success for the future.”

10th October 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics